Gencyte Therapeutics is focused on the development of the next-generation of Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy for precision cancer treatment. CAR-T involves adapting the immune system to target a patientÂ’s unique cancer variants. It offers the possibility of truly personalized medicine. There has been considerable recent interest in CAR-T, with six products recently being approved for use with patients. These therapies work well with blood cancers, such as leukemia. However, they have a number of drawbacks, including high toxicity and a lack of efficacy with solid tumors. This leaves many medical needs unmet. Gencyte Therapeutics is working on a novel strategy, which promises to be much less toxic, and treat a wider variety of cancers than the current therapies, including solid tumors. It would significantly expand the number of cancer patients who could benefit from this type of treatment.
